# Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable Therapy

> **NCT02843399** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 15498 (actual)

## Conditions studied

- Diabetes Mellitus Type 2

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02843399
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-15
- **Primary completion:** 2016-12-15
- **Final completion:** 2016-12-15
- **Target enrollment:** 15498 (ACTUAL)
- **Last updated:** 2017-12-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02843399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02843399, "Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02843399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*